Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
NCT06948487 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 12000
Last updated 2025-07-17
Summary
This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.
Conditions
- Gastritis
Sponsors & Collaborators
-
Daewoong Pharmaceutical Co. LTD.
lead INDUSTRY
Principal Investigators
-
Jingun Kim, Dr. · Masong Kim Internal Medicine Clinic
Eligibility
- Min Age
- 19 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-17
- Primary Completion
- 2025-11-30
- Completion
- 2027-06-03
Countries
- South Korea
Study Locations
More Related Trials
-
Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients
NCT02386007 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis
NCT03184415 ·Status: TERMINATED ·Phase: PHASE3
-
To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients
NCT03443804 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate Improvement Effect of Subjective Symptoms of Mucotra SR Tablet in Patients With Gastritis
NCT06668506 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia
NCT07016269 ·Status: RECRUITING ·Phase: PHASE4
-
To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient
NCT05163756 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis
NCT05493124 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Natural History of Non-steroidal Anti-inflammatory Drug and Non-Helicobacter Pylori in Bleeding Peptic Ulcers
NCT00153712 ·Status: COMPLETED
-
Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial
NCT06324825 ·Status: RECRUITING ·Phase: NA
-
Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia
NCT04449185 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of H. Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients
NCT02691637 ·Status: COMPLETED
-
Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia
NCT00990405 ·Status: UNKNOWN ·Phase: PHASE4
-
Observational Study on Monitoring NSAID-Induced Gastropathy in Patients Using Magnetically-Controlled Capsule Gastroscopy
NCT06027060 ·Status: SUSPENDED
-
Primary Care dySpEpsia rikkuNshiTo
NCT06482671 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Gastrogenic Microbiota in FD
NCT06760897 ·Status: COMPLETED ·Phase: NA
-
The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43
NCT02457104 ·Status: UNKNOWN
-
Objective Study on Tongue Diagnosis of Chronic Atrophic Gastritis
NCT06489132 ·Status: NOT_YET_RECRUITING
-
Duodenal Microbiota in Functional Dyspepsia
NCT06326918 ·Status: RECRUITING
-
Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet
NCT03437785 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation
NCT05388890 ·Status: RECRUITING
-
Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia
NCT06610266 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer
NCT00239551 ·Status: COMPLETED ·Phase: PHASE4
-
The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology
NCT04029441 ·Status: UNKNOWN
-
Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer
NCT01215058 ·Status: WITHDRAWN
-
Cytokine Gene Polymorphisms in Gastric Diseases
NCT00197470 ·Status: UNKNOWN ·Phase: NA